Personalized medicine firm MDxHealth SA (BSE:MDXH.BR) and its research partner NovioGendix B.V. won a $1.1 million grant to support the research and development of a new bladder cancer diagnostic.

The funding came from Eurotrans-Bio, a European Commission initiative that supports biotech R&D between companies and academia.